search
Back to results

Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)

Primary Purpose

Ataxia Telangiectasia (AT)

Status
Completed
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Conjugated pneumococcal vaccine (Prevenar)
Sponsored by
Institute of Child Health
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional basic science trial for Ataxia Telangiectasia (AT) focused on measuring Ataxia telangiectasia,, Conjugated pneumococcal,, Prevenar,, Immunogenicity ,, Vaccine

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Genetically confirmed diagnosis of AT

Sites / Locations

  • Great Ormond Street Hospital

Outcomes

Primary Outcome Measures

Immunogenicity of vaccine

Secondary Outcome Measures

Incidence of adverse reactions to vaccine

Full Information

First Posted
April 7, 2008
Last Updated
April 10, 2008
Sponsor
Institute of Child Health
Collaborators
Great Ormond Street Hospital for Children NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT00656409
Brief Title
Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)
Official Title
Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
June 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Institute of Child Health
Collaborators
Great Ormond Street Hospital for Children NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Ataxia Telangiectasia (AT) is an autosomal recessive inherited condition caused by mutations in the ATM gene1. Patients suffer from neuro-degenerative problems, usually commencing in the second year of life, and affecting predominantly the cerebellum. They also develop the characteristic superficial telangiectases. Between 60 and 80% of affected children are immunodeficient. This is associated with deficiency of immunoglobulin A (IgA ) 2, of IgG23 and of antibody responses to pneumococcal polysaccharides4. Patients suffer recurrent sino-pulmonary infections but a recent study suggests poor correlation between immune status and immunological parameters5. If uncontrolled, recurrent pulmonary infections can contribute to the development of chronic lung disease and bronchiectasis. Preventative management includes continuous prophylactic antibiotic treatment in some with the need for replacement immunoglobulin therapy in only a small proportion of cases. Antibiotics have been reasonably effective in this situation but the emergence of resistance amongst community acquired pneumococcal isolates is a cause for concern. Appropriate immunisation strategies may also have a role. This study is designed to look at antibody responses in a one versus two dose regimen in a cohort of AT patients recruited through the AT Society a national charitable organisation involved in providing support to families with this condition and in fostering education and research in the field.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ataxia Telangiectasia (AT)
Keywords
Ataxia telangiectasia,, Conjugated pneumococcal,, Prevenar,, Immunogenicity ,, Vaccine

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 3
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Conjugated pneumococcal vaccine (Prevenar)
Other Intervention Name(s)
Prevenar
Primary Outcome Measure Information:
Title
Immunogenicity of vaccine
Secondary Outcome Measure Information:
Title
Incidence of adverse reactions to vaccine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Genetically confirmed diagnosis of AT
Facility Information:
Facility Name
Great Ormond Street Hospital
City
London
ZIP/Postal Code
WC1N 3JH
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)

We'll reach out to this number within 24 hrs